VFA
VNDA icon

Valeo Financial Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Valeo Financial Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-106
Closed -$2K – 1734
2018
Q3 		$2K Buy
+106
New +$2.16K ﹤0.01% 1526

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Valeo Financial Advisors's VNDA Position: Q4 2018 in Review

Valeo Financial Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2018, closing a stake of 106 shares — an estimated $2K sold.

Valeo Financial Advisors first reported a position in VNDA in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 186 funds tracked by Wall St. Rank hold VNDA as of Q4 2018.

  • Valeo Financial Advisors reported no remaining Vanda Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Valeo Financial Advisors sold 106 Vanda Pharmaceuticals shares in Q4 2018, an estimated $2K.
  • Valeo Financial Advisors first reported a position in Vanda Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Valeo Financial Advisors's Vanda Pharmaceuticals position peaked at $2K in Q3 2018.
  • 186 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2018.

Based on Valeo Financial Advisors's 13F filing for Q4 2018, filed 30 Jan 2019.